Conclusion of the G Series G Shares subscription agreements
Current report No. 14/2020
Date: 29.01.2020 r.
Legal basis: Article 17(1) of MAR – inside information
With reference to current reports No. 11/2020 and 13/2020 and previous reports regarding the increase of the share capital through the issue of series G shares (“Series G Shares”), the Management Board of Medicalgorithmics S.A. with its registered office in Warsaw (“the Company”, “the Issuer”) informs that on 29 January 2020 the Company received information about the acceptance by investors of all bids submitted by the Company for subscription for 721.303 (seven hundred twenty one thousand three hundred and three) Series G Shares, in therefore, the Company hereby informs that it has concluded with investors subscription agreements for 721.303 (seven hundred twenty one thousand three hundred three) Series G Shares with a total value of 13,163,779.75 (thirteen million one hundred sixty three thousand seven hundred seventy nine zlotys 75/100) zlotys, counted as the product of the number of Series G Shares taken up and the issue price per one share of 18.25 (fifty-eight ) zlotys.
The Issuer’s Management Board also informs that the required cash contributions to cover Series G Shares have been made in full.
The advisors on the Company’s G Series Shares offer were: (i) Santander Bank Polska S.A. the Brokerage House operating by the organizational unit of Santander, which acted as the sole global coordinator and bookkeeper and (ii) CC Group sp.z o.o., which served as the financial advisor to the company.
This current report is for information purposes only. This current report does not in any way, directly or indirectly, promote the subscription of the Issuer’s new issue shares and is not promotional material prepared or published by the Company for the purpose of promoting the new issue of shares or their subscription or encouraging, directly or indirectly, to subscribe for them. The company has not yet published any materials aimed at promoting new issue shares or their subscription. This document is not an issue prospectus or other offer document, the preparation of which is not expected in connection with the issue of shares by the Company.
This material, as well as any part thereof, is not intended for distribution, directly or indirectly, in the territory or to the United States of America or in other countries where the public dissemination of information contained in this material may be restricted or prohibited by law. The securities referred to in this material have not been and will not be registered under the US Securities Act of 1933 as amended and may not be offered or sold in the territory of the United States of America with the exception of transactions that are not subject to registration as required by the US Securities Act or by virtue of an exception to such registration.
It is not disseminated, published or distributed, directly or indirectly, in the territory or to the United States of America, Australia, Canada, Japan or any other jurisdiction in which it is subject to restrictions or is not allowed.